DURHAM, N.C., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the 2017 Leerink Partners Rare Disease Roundtable Series on Wednesday, September 27, 2017 at 9:30 a.m. EDT in New York City.
A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease scheduled to undergo a procedure.
Contacts
Doug Blankenship
(919) 748-5975
dblankenship@dova.com
Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com